TipRanks Another day, another buy recommendation for Bionano. After Bionano Genomics (BNGO) posted a slight earnings miss two months ago, Maxim analyst Jason McCarthy was so pessimistic about the company’s prospects that he lowered his price target on the San Diego-based cytogenetics specialist’s stock from $4 to $10. McCarthy is sticking to his updated prediction two months later, and in a note issued yesterday, he reiterated his “buy” recommendation on the company as well — and why not? He hasn’t done a doub in two months./n
Read More
